("MaxCyte" or the "Company")
Result of AGM
Gaithersburg, MD - 01 November 2019: MaxCyte (LSE: MXCT, MXCR), the global cell-based therapies and life sciences company, announces that at its Annual General Meeting held yesterday, all resolutions were duly passed.
For further information, please contact:
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer
+1 301 944 1660
Nominated Adviser and Joint Corporate Broker
+44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
+44 (0)20 7260 1000
Financial PR Adviser
Consilium Strategic Communications
+44 (0)203 709 5700
MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including five commercial licenses. Aggregate potential pre-commercial milestones from all license deals total more than $450m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.